Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an announcement.
Hangzhou Tigermed Consulting Co., Ltd. announced that its wholly-owned subsidiary, Tigermed Japan Co., Ltd., has acquired a 56.37% equity interest in MICRON, a Japanese CRO specializing in medical imaging and clinical trial services. This acquisition enhances Tigermed’s presence in the Japanese market, leveraging MICRON’s reputation and technical capabilities in image analysis and clinical research. The acquisition is expected to strengthen Tigermed’s service offerings and market positioning in Asia, although MICRON has reported a net loss for the period from January to May 2025.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$38.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a leading contract research organization (CRO) based in China, specializing in providing clinical trial services to the pharmaceutical and biotechnology industries. The company focuses on delivering comprehensive services that support the development of new drugs and medical devices, with a strong emphasis on innovation and quality in clinical research.
YTD Price Performance: 71.67%
Average Trading Volume: 4,895,389
Technical Sentiment Signal: Buy
Current Market Cap: HK$53.66B
Find detailed analytics on 3347 stock on TipRanks’ Stock Analysis page.